30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
Do you offer free parking, snacks, coffee, paid leave to first responders, cell phone plans, financi...
Read More >
In a significant victory for employers and the principles of due process, the District of Minnesota ...
Read More >
Maslowski v. Prospect Funding Partners LLC, 2019 BL 25346, Minn. Ct. App., No. A18-1906 (July 8, 201...
Read More >
There continues to be new, complicated problems arising from the improper completion and use of off-...
Read More >
There is a lot currently happening in the European Union. From the latest European Court opinions wi...
Read More >
Private construction projects in New York will become subject to new prevailing wage requirements pu...
Read More >